# NovaBay Pharmaceuticals

NovaBay Pharmaceuticals is an Asset Manager based in Emeryville, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Emeryville, United States
- **Region:** North America
- **Assets under management:** Undisclosed
- **Website:** novabay.com
- **LinkedIn:** https://www.linkedin.com/company/novabay

## Regulatory record

- **Reports private funds:** No

## About

NovaBay Pharmaceuticals is a pharmaceutical company based in Emeryville, United States, established in 2000. It focuses on developing products for the eye care market and has secured $8.6 million in total funding.

## Sectors

- Digital Assets
- FinTech
- Infrastructure

## Questions

### How does SDEV generate returns?

SDEV generates returns primarily through staking its SKY governance tokens, earning protocol fees from the Sky Protocol's borrowing demand and on-chain activity. The firm also participates in governance decisions that influence Sky's economic parameters. It does not engage in short-term trading or speculation (per company SEC filings).

### What safeguards does SDEV have against market volatility?

SDEV prohibits speculative trading, margin, and derivatives without express authorization. It uses qualified U.S. custodians, maintains asset segregation, and separates operating capital from investment holdings. The firm also conducts independent audit reporting and continuously monitors regulatory developments (per company SEC filings).

### What is SDEV's exit or liquidity strategy for its SKY holdings?

SDEV describes its holdings as long-duration positions — not a trading operation. It has a warrant structure that includes a 10% daily volume cap post-exercise to ensure orderly market behavior. The firm maintains liquidity discipline by keeping operating capital separate.

### Does SDEV invest in tokens beyond SKY?

SDEV states its framework is designed to expand into additional protocol-aligned assets and operating opportunities over time. As of the latest disclosures, SKY is its initial and only disclosed holding. The firm explores revenue-generating opportunities such as liquidity provisioning and strategic partnerships across the stablecoin stack.

## Related profiles

- [Managed Markets Insight & Technology](https://altss.com/profile/managed-markets-insight-and-technology)
- [iUNU](https://altss.com/profile/iunu)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/novabay-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology